VENUSREM — Venus Remedies Share News
0.000.00%
Last trade - 00:00- IN₹16.56bn
- IN₹15.76bn
- IN₹7.70bn
Brief: Venus Remedies Gets Market Authorizations In Saudi Arabia And Philippines
Brief: India's Venus Remedies Ltd Sept-Quarter Consol Net Profit Rises
India's Venus Remedies gains after govt confers three star export house status
Brief: Venus Remedies Gets 'Three Star Export House' Certificate From India Govt
India's Venus Remedies jumps on market authorisation for cancer drug in UK
Brief: Venus Remedies Granted Market Authorization For Bleomycin 15,000 IU In UK
India's Venus Remedies gains on marketing nod for chemo drugs
Brief: Venus Remedies Says Consolidates In ASEAN, Gets Marketing Approval For Six Chemotherapy Drugs From Philippines
Brief: Venus Remedies Extends Its Oncology Portfolio In South Eastern Europe With Serbian Marketing Approval For Gemcitabine, Docetaxel
Brief: Venus Remedies Gets Department Of Scientific And Industrial Research Registration For Customs Duty Exemption
India's Venus Remedies up on Saudi marketing approval for syringes
Brief: Venus Remedies Gets Saudi Marketing Approval For Enoxaparin In Pfs
Brief: Venus Remedies Launches Its Flagship Research And Development Drug Elores In Oman
Brief: Venus Remedies Says Trading In Shares Of Co Restricted By BSE And NSE
Brief: Venus Remedies Gets Marketing Approvals From Four Key Markets For Chemotherapy Drugs
India's Venus Remedies jump on Spain approving anti-bacterial drug
Brief: Venus Remedies Gets Approval To Market Generic Drug Meropenem In Spain
Brief: Venus Remedies Awarded Ukrainian GMP Approval For Its Carbapenem, Oncology Parenteral Facilities
India's Venus Remedies up 4.6% on Saudi marketing approval for chemotherapy drug